A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.

Publication Type:

Journal Article

Source:

Cancer, Volume 120, Issue 11, p.1647-55 (2014)

Keywords:

2014, Center-Authored Paper, Clinical Research Division, March 2014, Shared Resources, Specimen Processing Core Facility

Abstract:

Multitargeted tyrosine kinase inhibitors (TKIs) have antitumor activity in metastatic renal cell carcinoma (mRCC). Resistance to these agents develops frequently, and their use is often limited by intolerance. Ramucirumab is a recombinant human monoclonal antibody directed against human vascular endothelial growth factor receptor-2. For this study, the authors investigated the clinical efficacy and safety of ramucirumab in patients with TKI-resistant/intolerant mRCC.